Get the Stockscreener App
4.67
1.74%
0.08
After Hours:
4.68
0.010
+0.21%
Ironwood Pharmaceuticals Inc stock is traded at $4.67, with a volume of 4.45M.
It is up +1.74% in the last 24 hours and up +31.92% over the past month.
Ironwood Pharmaceuticals Inc is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal, or GI, and rare diseases. It is focused on the development and commercialization of inventive product opportunities in areas of unmet need, leveraging its demonstrated expertise and capabilities in GI and rare diseases. LINZESS is its commercial product. LINZESS is also available for the treatment of adults with IBS-C or CIC in Mexico, adults with IBS-C or chronic constipation in Japan, and adults with IBS-C in China. Linaclotide is available under the trademarked name CONSTELLA for the treatment of adults with IBS-C or CIC and pediatric patients ages 6-17 years old with FC in Canada, and to adults with IBS-C in certain European countries.
See More
Previous Close:
$4.59
Open:
$4.64
24h Volume:
4.45M
Relative Volume:
1.63
Market Cap:
$768.74M
Revenue:
$296.15M
Net Income/Loss:
$24.02M
P/E Ratio:
38.72
EPS:
0.1206
Net Cash Flow:
$127.01M
1W Performance:
+11.19%
1M Performance:
+31.92%
6M Performance:
+126.70%
1Y Performance:
+403.40%
1-Day Range:
$4.555
$4.73
1-Week Range:
$4.0802
$4.73
52-Week Range:
$0.5271
$5.78
Ironwood Pharmaceuticals Inc Stock (IRWD) Company Profile
Name
Ironwood Pharmaceuticals Inc
Sector
Phone
617-621-7722
Address
100 SUMMER STREET, SUITE 2300, BOSTON, MA
Compare IRWD vs TAK, ZTS, TEVA, HLN, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IRWD
Ironwood Pharmaceuticals Inc
|
4.67 | 755.58M | 296.15M | 24.02M | 127.01M | 0.1206 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Ironwood Pharmaceuticals Inc Stock (IRWD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
| Apr-15-25 | Downgrade | Jefferies | Buy → Hold |
| Apr-15-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-14-25 | Downgrade | Citizens JMP | Mkt Outperform → Mkt Perform |
| Sep-09-24 | Initiated | Leerink Partners | Market Perform |
| Aug-08-24 | Downgrade | CapitalOne | Overweight → Equal Weight |
| Jan-17-24 | Initiated | Craig Hallum | Buy |
| Dec-14-23 | Initiated | Wells Fargo | Overweight |
| Nov-09-23 | Initiated | Jefferies | Buy |
| Sep-28-23 | Initiated | JMP Securities | Mkt Outperform |
| Sep-02-22 | Initiated | CapitalOne | Overweight |
| Apr-22-22 | Initiated | Piper Sandler | Overweight |
| Sep-30-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-20 | Initiated | Northland Capital | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Neutral |
| Mar-27-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Feb-25-19 | Upgrade | H.C. Wainwright | Sell → Neutral |
| Jan-24-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-07-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| Nov-07-18 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-23-18 | Initiated | H.C. Wainwright | Sell |
| May-09-18 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jan-05-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-06-17 | Downgrade | Mizuho | Buy → Neutral |
| Jul-21-17 | Downgrade | JP Morgan | Overweight → Neutral |
| May-03-17 | Initiated | Wells Fargo | Outperform |
| Apr-07-17 | Reiterated | Mizuho | Buy |
| Feb-22-17 | Reiterated | Barclays | Equal Weight |
| Nov-04-16 | Reiterated | Mizuho | Buy |
| Oct-24-16 | Reiterated | Wedbush | Neutral |
| Oct-10-16 | Reiterated | Mizuho | Buy |
| Sep-27-16 | Reiterated | WallachBeth | Hold |
View All
Ironwood Pharmaceuticals Inc Stock (IRWD) Latest News
Ironwood Pharmaceuticals (IRWD) price target increased by 28.97% to 7.04 - MSN
Ironwood Pharmaceuticals Inc expected to post earnings of 24 cents a shareEarnings Preview - TradingView
Ironwood Pharmaceuticals (IRWD) Highlights Provider Insights on TPN for SBS Treatment - GuruFocus
Why fewer TPN days matter: doctors cite infection, pain in short bowel syndrome - Stock Titan
MSN Money - MSN
IRWD News | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Press Release: Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call - Moomoo
Ironwood Pharmaceuticals to Host First Quarter 2026 Investor Update Call - ChartMill
IRWD Technical Analysis | Trend, Signals & Chart Patterns | IRONWOOD PHARMACEUTICALS INC (NASDAQ:IRWD) - ChartMill
Ironwood Pharmaceuticals (IRWD) Projected to Post Earnings on Wednesday - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Up 7.3%Here's What Happened - MarketBeat
[ARS] IRONWOOD PHARMACEUTICALS INC SEC Filing - Stock Titan
Ironwood (NASDAQ: IRWD) seeks 10M more equity plan shares in 2026 proxy - Stock Titan
Ironwood Pharmaceuticals (IRWD) price target increased by 10.31% to 5.46 - MSN
Book value per share of Ironwood Pharmaceuticals, Inc. Class A – SWB:I76 - TradingView
Bank of America (NASDAQ: IRWD) reports 6.1% stake in Ironwood Pharmaceuticals - Stock Titan
IRWD Price Today: Ironwood Pharmaceuticals, Inc.Stock Price, Quote & Chart | MEXC - MEXC Exchange
Ironwood (IRWD) to Present Landmark Survey Data at DDW 2026 - GuruFocus
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutritio - PharmiWeb.com
Zacks Research Has Bearish Estimate for IRWD Q2 Earnings - MarketBeat
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026 - Yahoo Finance
Zacks Research Issues Positive Outlook for IRWD Earnings - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Down 6%Here's What Happened - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Given Average Rating of "Hold" by Brokerages - MarketBeat
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Short Interest Update - MarketBeat
Ironwood Pharmaceuticals (IRWD) Stock Put Call Ratio (Momentum Building) 2026-04-15Trading Ideas - Cổng thông tin điện tử tỉnh Lào Cai
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading 7.8% HigherStill a Buy? - MarketBeat
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap UpWhat's Next? - MarketBeat
Ironwood (IRWD) is one of the most attractive small-cap drug manufacturers, here is why - MSN
What events could move Ironwood Pharmaceuticals (IRWD) Stock next | Price at $3.58, Down 1.52%High Yield Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Price Passes Above Two Hundred Day Moving AverageShould You Sell? - MarketBeat
New Highs: Is Ironwood Pharmaceuticals Inc affected by consumer sentimentM&A Rumor & Consistent Profit Alerts - baoquankhu1.vn
Is trend weakening for Ironwood Pharmaceuticals (IRWD) Stock | Price at $3.46, Down 1.98%Swing Signals - Cổng thông tin điện tử Tỉnh Sơn La
Breakout Move: Will Ironwood Pharmaceuticals Inc outperform the market in YEAR2026 Chart Watch & Intraday High Probability Setup Alerts - baoquankhu1.vn
Will Ironwood Pharmaceuticals (IRWD) Stock Miss Expectations | IRWD Q4 Earnings: Misses Estimates by $0.02Social Buy Zones - UBND thành phố Hải Phòng
Support Test: Does Ironwood Pharmaceuticals Inc have consistent dividend growth2026 EndofMonth & High Win Rate Trade Tips - baoquankhu1.vn
Ironwood Pharmaceuticals (NASDAQ:IRWD) Trading Down 5.8%Time to Sell? - MarketBeat
Ironwood Pharmaceuticals Inc Stock (IRWD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
2.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):